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Greatly waned neurogenesis, diminished microvasculature, astrocyte hypertrophy and activated microglia
are among themost conspicuous structural changes in the aged hippocampus. Because these alterations can
contribute to age-related memory and mood impairments, strategies efficacious for mitigating these
changesmay preserve cognitive andmood function in old age. Resveratrol, a phytoalexin found in the skin of
red grapes having angiogenic and antiinflammatory properties, appears ideal for easing these age-related
changes. Hence, we examined the efficacy of resveratrol for counteracting age-related memory and mood
impairments and the associated detrimental changes in the hippocampus. Two groups of male F344 rats in
late middle-age having similar learning and memory abilities were chosen and treated with resveratrol or
vehicle for four weeks. Analyses at ,25 months of age uncovered improved learning, memory and mood
function in resveratrol-treated animals but impairments in vehicle-treated animals. Resveratrol-treated
animals also displayed increased net neurogenesis and microvasculature, and diminished astrocyte
hypertrophy and microglial activation in the hippocampus. These results provide novel evidence that
resveratrol treatment in late middle age is efficacious for improving memory andmood function in old age.
Modulation of the hippocampus plasticity and suppression of chronic low-level inflammation appear to
underlie the functional benefits mediated by resveratrol.
T
he hippocampus, a region of the brain vital for functions such as learning, memory and mood, is highly
vulnerable to normal aging and Alzheimer’s disease (AD)1. Because the pathogenesis leading to AD includes
an extended latent phase and a shorter prodromal, mild cognitive impairment (MCI) phase2, drug inter-
ventions that can prevent MCI in old age have immense importance. Such drugs may be prescribed to the aging
population if they are efficacious for maintaining normal cognitive and mood function in old age with no or
minimal side effects. Decreased function in the dentate gyrus (DG) of the hippocampus has been considered as
one of the key reasons for memory and mood dysfunction seen in old age3,4. The DG exhibits a unique form of
neural circuit plasticity all through life called ‘‘adult hippocampus neurogenesis’’5–7. Interestingly, neurons that
are born in the adult DG play important roles in memory and mood function6,8–10. Because aging is associated
with greatly diminished hippocampal neurogenesis11–13, the proposition that declined neurogenesis contributes to
memory andmood dysfunction in the aged population has emerged. This concept has been supported bymultiple
studies14. These include observations that middle-aged/aged animals housed in enriched environment, perform-
ing voluntary physical exercise or exhibiting lower corticosterone levels display improved cognitive function in
association with enhanced hippocampus neurogenesis15–18. Furthermore, progenitor cells in the hippocampus of
depressed patients exhibit decreased proliferation than age-matched controls19.
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Studies in rat models suggest that aging does not diminish the
numbers of putative hippocampal neural stem/progenitor cells
(NSCs) or impair the neuronal differentiation and survival of newly
born cells12,13,20. However, the fraction of quiescent NSCs increases in
the aged hippocampus20,21. This is likely due to changes in the DG
milieu, as neurotrophic factors and signaling molecules that stimu-
late the proliferation of NSCs decline in concentration with
aging22–25. Moreover, other factors that are considered detrimental
for neurogenesis also emerge in the aged hippocampus. These
include chronicmild inflammationmanifesting in the form of hyper-
trophy of astrocytes and activation of microglia26,27, decreased avail-
ability of astrocyte-derived pro-neurogenic factors23,28 and decreased
microvasculature29. From this perspective, drugs having ability for
restraining inflammation and enhancing microvasculature in the
aged hippocampus are likely beneficial for stimulating quiescent
NSCs to produce new neurons in the aged hippocampus. Increased
neurogenesis and microvasculature and reduced inflammation may
help in the maintenance of adequate memory and mood function in
the normal elderly population.
Administration of resveratrol (RESV), a naturally occurring poly-
phenol found in high concentrations in the skin of red grapes,
appears suitable for counteracting age-related detrimental changes
in the hippocampus because of its pro-angiogenic and antiinflam-
matory properties with no adverse side effects30–33. Indeed, RESV has
been shown to mediate a wide range of biological activities including
extension of the life span and delayed onset of age related dis-
eases31,34–36. Furthermore, RESV readily crosses the blood brain bar-
rier and its activity in the brain lasts for up to 4 hrs37. Additionally,
recent studies provide evidence that RESV intake in healthy older
persons improves memory performance38 and RESV has antidepres-
sant effects in an animal model of depression39. Therefore, in this
study, we rigorously examined the efficacy of intraperitoneal admin-
istration of RESV for maintaining/improving cognitive and mood
function in agedmale F344 rats. To understandmechanisms, we also
investigated whether RESV therapy can increase neurogenesis and
microvasculature, and modulate the hypertrophy of astrocytes and
activation of microglia, in the aged hippocampus.
Results
Two groups of rats in late middle age (21-month old) chosen for the
study displayed similar ability for spatial learning and memory
formation. Figure 1 illustrates the time-line of treatment, behavioral
tests and other analyses. Characterization using a water maze test
(WMT) revealed that the two groups of 21-months old rats chosen
for this study exhibited similar learning and memory ability prior to
the commencement of treatment regimen (Fig. 2). Animals assigned
to both groups also exhibited similar swim speed (p. 0.05, F 5 3.73,
Fig. 2 [A1]) across learning sessions. Two-way repeated measures
analyses of variance (RM-ANOVA) revealed progressive and
comparable decreases in latencies to reach the platform over seven
training sessions in both groups (p , 0.0001, F 5 9.66, Fig. 2 [A2]).
Hence, learning curves did not differ between the two groups (p .
0.05, F 5 2.23, Fig. 2 [A2]). Analyses of swim path efficiency (i.e. the
ratio of the shortest possible swim path length to actual swim path
length) demonstrated that both groups displayed comparable
improvement in swim path efficiency values over seven learning
sessions (p , 0.0001, F 5 7.2) and hence their swim path efficiency
curves were similar (p. 0.05, F 5 0.55, Fig. 2 [A3]). Analyses of data
from memory retrieval test performed 24 hours after the last learning
session also showed similar results (Fig. 2 [B1–C1]). Animals in both
groups showed a clear affinity for the platform quadrant (PQ, the
quadrant where platform was placed during learning sessions),
which was evidenced through considerably greater dwell time in
PQ, in comparison to all other quadrants (p , 0.05–0.001, F 5
6.5–9.2, one-way ANOVA, Fig. 2 [B2, B3]). Additional parameters
such as dwell times in PQ and platform area (PA, a smaller area within
the PQ denoting the actual position of the platform and an immediate
surrounding region) and platform area crossings were also similar
between the two groups (p . 0.05, Fig. 2 [C1–C3]).
RESV treatment in late middle age improved ability for spatial
learning and spatial memory formation at an advanced age. The
two groups of rats described above received either vehicle (VEH) or
RESV for four weeks when they were in the 23rd month of their life. A
month later (i.e. in 25th month of their life), a second WMT was
performed to assess their ability to make new spatial memories.
Animals belonging to both VEH and RESV groups learned to
locate the position of submerged platform during training sessions.
Two-way RM-ANOVA showed that there were no differences in
swim speeds between the two groups (p . 0.05, F 5 0.3, Fig. 3
[A1]). Furthermore, progressive decreases in latencies to reach the
platform over training sessions were seen in both groups (p ,
0.0001, F 5 12.27, Fig. 3 [A2]). However, learning curves differed
Figure 1 | A cartoon depicting the time-line of various experiments. A cohort of 21-months old rats was examined using a water maze test (WMT) and
animals with normal spatial learning and memory function were chosen and divided into two groups. One of the groups then received vehicle
(VEH, n5 7) and the other group received resveratrol (RESV, n5 8) for four weeks. Animals in both groups also received 59-bromodeoxyuridine (BrdU)
in the last week of VEH or RESV treatment to facilitate the labeling and quantification of newly born cells and neurons. Both groups underwent a second
WMT four weeks after the termination of VEH or RESV treatment followed by a forced swim test (FST). Animals were next euthanized via intracardiac
perfusions and brain tissues processed for immunohistochemical staining and various quantifications.
www.nature.com/scientificreports
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significantly between the two groups (p, 0.0001, F 5 204.17, Fig. 3
[A2]) because RESV-treated rats displayed much superior learning.
This was evidenced through considerably shorter latencies to reach
the platform in all learning sessions in RESV-treated aged rats, in
comparison to VEH-treated aged rats (p , 0.001–0.0001). Swim
path efficiency curves also differed significantly between RESV-
and VEH-treated groups (p , 0.001, F 5 60.53, Fig. 3 [A3]). In
comparison to VEH-treated rats, RESV-treated rats displayed
significantly greater swim path efficiency values for all learning
sessions except session 6 (p , 0.05–0.01). Thus, RESV-treated rats
displayed much superior ability for spatial learning than VEH-
treated rats. Analyses of data from the memory retrieval test
performed 24 hours after the last learning session demonstrated
impaired ability in VEH-treated rats but preserved ability for
spatial memory formation in RESV-treated rats (Fig. 3 [B1–C3]).
Aged rats treated with VEH displayed no affinity for PQ over
other quadrants in the probe test (p . 0.05, F 5 1.54, Fig. 3 [B1,
C1]). In contrast, aged rats treated with RESV demonstrated greater
Figure 2 | Spatial learning and memory performance comparison between the two 21-months old animal groups chosen for vehicle (VEH, n5 7) or
resveratrol (RESV, n5 8) treatment. There were no differences between the two groups for swim speed (A1; p. 0.05, two-way ANOVA), latencies to
reach the platform (A2; p . 0.05) or swim path efficiency (A3; p . 0.05) in different learning sessions. Probe test conducted 24 hours after the last
learning session revealed similar results (B1–B3). Both groups chosen for VEH (B2) or RESV (B3) treatment showed greater affinity for the platform
quadrant, in comparison to the other three quadrants of the pool (one-way ANOVA, p, 0.05–0.001). Additional parameters of memory retrieval ability
such as the dwell time in the platform quadrant (C1), platform area crossings (C2) and dwell time in platform area (C3) were also comparable between the
two groups (p . 0.05). PQ (NE-Q), platform quadrant (northeast quadrant); SE-Q, southeast quadrant; SW-Q, southwest quadrant; and NW-Q,
northwest quadrant. *, p , 0.05, **; p , 0.01; ***; p , 0.001.
www.nature.com/scientificreports
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dwell times in the PQ, in comparison to all other quadrants (one-way
ANOVA, p , 0.0001; post-hoc tests, p , 0.001, F 5 29.30, Fig. 3
[B2, C2]). Direct comparison of dwell times in the PQ also showed
clear differences between RESV- and VEH-treated groups (p ,
0.001, Fig. 3 [C3]).
Analyses of spatial learning data between pre- and post-treatment
periods in the VEH group showed that spatial learning ability neither
improved nor worsened between 22 and 25 months of age. At both
time-points, rats displayed similar progressive decreases in latencies
to reach the platform (p, 0.0001, F 5 11.2, Fig. 4 [A1]) and hence
learning and swim path efficiency curves remained comparable (p.
0.05, F 5 0.14–1.7, Fig. 4 [A1, A2]). Nonetheless, these rats lost
ability for spatial memory formation by 25 months of age, which
was evidenced through their lack of affinity towards PQ in the mem-
ory retrieval test conducted after the secondWM training (p. 0.05,
F 5 1.54, Fig. 3 [C1]). Direct comparison revealed significantly
reduced dwell times of these rats in PQ in the probe test performed
after the second WMT (p , 0.05, Fig. 4 [A3]). In contrast, RESV-
Figure 3 | Spatial learning and memory performance comparison between the vehicle (VEH, n 5 7) treated and resveratrol (RESV, n 5 8) treated
animal groups, in the second water maze test performed four weeks after the termination of VEH or RESV treatment. Swim speeds were comparable
between the two groups (A1; p . 0.05, two-way ANOVA) and both groups displayed ability for spatial learning (A2; p , 0.0001, repeated
measures ANOVA). However, RESV treated rats displayed much superior learning than VEH treated rats (A2; p, 0.0001, two-way ANOVA) and this
was also revealed through much improved swim path efficiency values in RESV treated animals (A3; p , 0.001). B1 and B2 illustrate swim paths of
representative rats from VEH (B1) and RESV (B2) groups in a single-trial probe test conducted 24 hours after the last learning session whereas, figure B3
shows the position of four quadrants, the platform area and the target area in the water maze pool during the probe test. Note that, VEH treated rats
showed almost equal affinity for all four quadrants (B1 and C1; p . 0.05, one-way ANOVA), implying memory retrieval dysfunction in these rats. In
contrast, RESV treated rats exhibited a clear affinity for the platformquadrant over all other quadrants (B2, C2; p, 0.001). This difference is also apparent
froma direct comparison of the dwell time in the platformquadrant across the two groups (C3; p, 0.001, two-tailed, unpaired Student’s t-test). PQ (SW-
Q), platform quadrant (southwest quadrant); NW-Q, northwest quadrant; NE-Q, northeast quadrant; SE-Q, southeast quadrant. ***, p , 0.001.
www.nature.com/scientificreports
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treated aged animals displayed improved spatial learning perform-
ance. This was revealed through superior curves for learning (p ,
0.0001, F 5 35.18, Fig. 4 [B1]) as well as swim path efficiency in the
post-treatment period (p , 0.01, F 5 12.3, Fig. 4 [B2]). These rats
also showed improved ability for spatial memory formation, which
was seen through further increases in their affinity for PQ versus
other quadrants (p, 0.01 in the probe test conducted after the first
WM training, Fig. 2 [B2]; p , 0.0001 in the probe test conducted
after the secondWM training, Fig. 3 [C2]). Additionally, direct com-
parison showed increased dwell times of RESV-treated rats in PQ, in
the probe test performed after the second WM training (p , 0.05,
Fig. 4 [B3]). Thus, in the absence of therapeutic treatment, aged rats
can maintain their spatial learning ability but lose their capacity for
making new spatial memory between 22 and 25 months of age. In
Figure 4 | Pre- and post-treatment spatial learning and memory performance comparison in vehicle (VEH, n 5 7) and resveratrol (RESV, n 5 8)
treated aged rats.Rats treated with VEH retain the ability for spatial learning at pre-treatment levels, which is evident from their learning curves (A1; p.
0.05, two-way ANOVA) and swim path efficiency values (A2; p. 0.05). However, they exhibit memory retrieval dysfunction (A3; p, 0.05). In contrast,
RESV treated rats display improved ability for spatial learning andmemory retention in comparison to their pre-treatment performance. This is obvious
from comparison of pre- and post-RESV treatment learning curves (B1, p, 0.0001), swim path efficiency values (B2; p , 0.01) and dwell time in the
platform quadrant (B3; p, 0.01). (C1–C3): Comparison of depressive-like behavior in a forced swim test between VEH treated and resveratrol (RESV)
treated aged rats. Note that, RESV treated aged rats displayed reduced depressive-like behavior, in comparison toVEH treated aged rats. The differences in
floating time (or immobility) during the test were significant for the first five minutes of the test (C1; p, 0.05) as well as for the entire duration of the test
(C3; p , 0.05) but not significant for the last 5 minutes of the test (C2; p . 0.05, two-tailed, unpaired Student’s t-test). *, p , 0.05, **; p , 0.01.
www.nature.com/scientificreports
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contrast, with RESV treatment, aged rats showed an improved ability
for both spatial learning and spatial memory during this period.
To further investigate the improved learning ability displayed by
aged animals after RESV-treatment (i.e. in the second WMT), we
compared latencies to reach the platform between the four trials
performed on day 1 (i.e. the first learning session). While, RM-
ANOVA analysis did not show statistically significant decreases in
latency values (p. 0.05, F 5 2.3), the overall percentage reductions
in latency values over four trials suggested improved learning ability.
Latency values were decreased by 55% between trials 1 and 2, 59%
between trials 2 and 3 and 47% between trials 3 and 4 (Table 1 in
supplement document). In contrast, VEH-treated animals did not
show percentage decreases between trials 1 and 2 or 3 and 4, and
showed only 22% decrease between trials 2 and 3 (p. 0.05, F5 0.37;
Table 1 in supplement document). Thus, an improved learning abil-
ity of RESV-treated aged rats could be observed in the very first
learning session. Furthermore, to examine whether overnight forget-
ting underlies impaired memory retrieval function in VEH-treated
animals, we performed additional analyses on their spatial learning
parameters. First, we compared the last trial (trial 4 or T4) latency
values in every learning session (S) with the first trial (T1) latency
values of the subsequent learning session (Table 2 in supplement
document). Next, we compared average latency values of each of
sessions 1–6 with T1 latency values of the subsequent learning ses-
sion (T1 of S2–S7, Table 3 in supplement document). Both of these
analyses did not imply the occurrence of overnight forgetting during
learning in VEH-treated animals (Tables 2 and 3 in supplement
document). However, their overall latency values decreased over
seven learning sessions as they continuously improved their learning
in subsequent learning sessions.
From their behavior, it appeared that RESV-treated animals
remembered the logistics involved in finding the hidden platform
from the first WMT (performed prior to treatment) better than
VEH-treated animals. This was apparent from their ability to quickly
locate the hidden platform by the second learning session, which
allowed stronger memory encoding to occur in the remaining learn-
ing sessions (i.e. in learning sessions 3–7, Fig. 3 [A2]). This is in sharp
contrast to VEH-treated rats, which showed progressive decreases in
latency values over seven learning sessions but ended up having
much higher latency values than RESV treated animals even in the
7th session of learning (Fig. 3 [A2]). Thus, VEH-treated animals
remained in the learning phase over 7 sessions of learning whereas
RESV-treated animals learned to quickly locate the platform within
the first two sessions of learning and utilized the remaining sessions
of learning for memory encoding.
RESV treatment did not alter motor function in VEH or RESV
treated aged rats. Comparison of swim speeds of animals belonging
to VEH and RESV treated groups across pre- and post-treatment
periods revealed no differences in swim speeds (p . 0.05, Fig. 1 in
supplement document). Thus, VEH or RESV treatment did not
significantly alter the motor ability of aged rats. We did not
perform visible platform test following spatial learning and
memory test in this study as animals belonging to both VEH and
RESV groups showed ability for spatial learning in both first
and second WMTs. Hence, it is unknown whether RESV
treatment improved vision function of aged rats in this study.
Additional studies are needed in the future on possible RESV-
mediated vision improvements in aged rats.
RESV treatment improvedmood function in aged rats.Analyses of
immobility (or floating) time in a forced swim test (FST) was used as
ameasure of depressive-like behavior in VEH and RESV treated rats,
as rats with normal mood function are known to spend reduced
amounts of the test time in floating. In the first five minutes of the
test, RESV-treated aged rats spent reduced amount of time in floating
than VEH-treated aged rats (34% reduction, p, 0.05, Fig. 4 [C1]). A
similar trend was also observed in the final five minutes of the test
(32% reduction, p . 0.05, Fig. 4 [C2]). When floating times for the
entire 10 minutes duration were compared, it was clear that RESV-
treated rats displayed decreased tendency for floating (127.2 6 12.9
seconds) than VEH-treated aged rats (188.2 6 17.2 seconds, p ,
0.05, Fig. 4 [C3]). Thus, RESV treatment to aged rats resulted in an
anti-depressant effect, implying improved mood function. However,
as only FST was used for measuring depressive-like behavior in this
study, additional behavioral tests measuring depression will be
required in future studies to confirm the anti-depressive effects of
RESV in aged rats.
RESV treatment enhanced net neurogenesis in the hippocampus
of aged rats. Quantification of the total number of 59-
bromodeoxyuridine (BrdU) positive cells revealed increased
addition of newly born cells to the subgranular zone-granule cell
layer (SGZ–GCL) of aged rats receiving RESV treatment, in
comparison to aged rats receiving VEH treatment (Fig. 5 [A1–G]).
The addition of new cells was increased by 1.8-folds with RESV
treatment (p , 0.05; Fig. 5 [E]). Quantification of fractions of
newly born cells that differentiate into NeuN-expressing neurons
in the SGZ-GCL (using dual immunofluorescence and confocal
microscopy, Fig. 5 [C1–D3]) suggested no significant difference in
neuronal differentiation of newly born cells between VEH and
RESV-treated aged animals (p . 0.05, Fig. 5 [F]). Through
extrapolation of BrdU1 cell numbers with the percentage of
newly born cells expressing neuron-specific nuclear antigen
(NeuN), we calculated net neurogenesis value for each animal and
compared between the two groups. This analysis showed that RESV
treatment to aged rats induced 2.4-folds increase in net hippocampal
neurogenesis (p, 0.01, Fig. 5 [G]). Since BrdU injections were given
during the last 7 days of RESV treatment, these results showed the
extent of neurogenesis occurring in the 4th week of RESV treatment.
RESV treatment promoted increased neurogenesis in aged rats for
prolonged periods. We also analyzed neurogenesis through
quantification of neurons positive for doublecortin (DCX, a
marker of newly born neurons) in the SGZ-GCL (Fig. 6 [A1–D]).
SinceDCX expression in newly born neurons lasts for,2weeks after
their birth in F344 rats40, this analyses provided ameasure of ongoing
neurogenesis. Aged rats treated with RESV exhibited 2.1 folds
increase in DCX1 newly born neurons than aged rats receiving
VEH (p , 0.001, Fig. 6 [D]). Since these neurons are generated
,6 weeks after the termination of RESV treatment, the results
suggest that RESV treatment can trigger sustained increase in
neurogenesis in the aged hippocampus even after its termination.
RESV treatment enhancedmicrovasculature in the hippocampus of
aged rats. To determine whether RESV treatment improved cerebral
blood flow, we measured microvasculature in the hippocampus using
rat endothelial cell antigen-1 (RECA-1) immunostaining (Fig. 7 [A1–
D4]). Area fraction analyses demonstrated increased microvasculature
in RESV-treated rats, in comparison to VEH-treated rats (Fig. 7 [D1–
D4]). The increase was significant for the CA1 subfield and the entire
hippocampus (p , 0.05–0.01, Fig. 7 [D2, D4]).
RESV treatment reduced the hypertrophy of astrocytes in aged
rats. Immunohistochemical staining for glial fibrillary acidic protein
(GFAP) suggested increased occurrence of astrocytes with
hypertrophy in VEH-treated rats, in comparison to RESV-treated
rats (Fig. 7 [E1–G2]). Therefore, we measured the area fraction of
GFAP1 astrocyte elements (soma and processes) in different
subfields of the hippocampus. This quantification revealed reduced
astrocyte hypertrophy in the hippocampus of RESV-treated aged
rats. The reductions varied from 42 to 45% for different subfields
of the hippocampus (p , 0.001, Fig. 7 [H1–H3]). When the
www.nature.com/scientificreports
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Figure 5 | Examples of newly born cells expressing 59-bromodeoxyuridine (BrdU) in the subgranular zone-granule cell layer (SGZ-GCL) of the
hippocampus from a rat that received vehicle (VEH) treatment (A1) and a rat that received resveratrol (RESV) treatment (B1). (B1 and B2) aremagnified
views of regions from A1 and B1. Figures (C1–D3) show examples of BrdU1 newly born cells that mature and express neuron specific nuclear antigen
(NeuN). Bar charts compare numbers of newly born (BrdU1) cells (E), percentages of newly born cells expressing NeuN (F) and net hippocampal
neurogenesis (G) between VEH and RESV treated groups (n5 6/group). Note that, both numbers of newly born cells and net hippocampal neurogenesis
are greater in RESV treated rats than VEH treated rats (p, 0.05–0.01, two-tailed, unpaired, Student’s t-test). *, p, 0.05, **; p, 0.01. Scale bar, A1 and
B1, 100 mm; A2 and B2, 50 mm; C1–D3, 10 mm.
www.nature.com/scientificreports
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hippocampus was taken in entirety, the overall decrease was 44%
(p , 0.001, Fig. 7 [H4]).
RESV treatment reduced activation of microglia in aged rats.
Immunohistochemical characterization using OX-42 (CD11b)
antibody revealed increased occurrence of activated microglia
displaying enlarged soma and fewer processes in VEH-treated rats,
resulting in larger spaces between microglia (Fig. 8 [A1, B1, C1]). In
contrast, RESV-treated rats showed mostly ramified microglia (i.e.
restingmicroglia exhibiting very extensive fine processes) (Fig. 8 [A2,
B2, C2]). Hence, we quantified the area fraction of OX-421
microglial elements (soma and processes) in the hippocampus.
This measurement suggested increased occurrence of ramified or
resting microglia in RESV-treated rats than VEH-treated rats
(Fig. 8 [D1–D4) and differences were significant for the CA1
subfield and the entire hippocampus (p , 0.05, Fig. 8 [D2, D4]).
To confirm this further, we performed tracing of OX-421 microglia
and its processes from both VEH- and RESV-treated groups using
Neurolucida (Fig. 8 [E1, E2]). This quantification showed that, in
comparison to microglia in VEH-treated aged rats, microglia in
RESV-treated animals displayed 25% greater numbers of segments
in their processes (p, 0.05, Fig. 8 [F1]) and 35% greater total process
length (p , 0.05, Fig. 8 [F2]). Furthermore, the concentric circle
analysis of Sholl revealed that, microglia from RESV-treated aged
rats exhibited greater numbers of intersections at 0-10 mm and 20–
30 mm distances from the soma (Fig. 8 [F3]), and greater number of
process endings at 0–50 mm distance from the soma, in comparison
to microglia from VEH-treated aged rats (p , 0.05, Fig. 8 [F4]).
These results implied that most microglia in RESV-treated rats
have highly ramified appearance whereas considerable numbers of
microglia in the VEH-treated aged rats have modified into activated
microglia with fewer processes. To authenticate this possibility
further, we performed immunostaining for ED-1 (CD68, a specific
marker of activatedmicroglia exhibiting amoeboidmorphology) and
quantified the numbers of ED-11 cells in the DG (Fig. 9 [A1–C]).
This showed that VEH-treated rats contained 29% greater numbers
of activated microglia than RESV-treated aged rats (p , 0.05, Fig. 9
[C]). Collectively, these results confirmed that RESV-treatment in
old age reduced the presence of activated microglia in the
hippocampus.
RESV treatment did not alter the volume of hippocampus. To
ascertain the effects of RESV treatment on hippocampus volume,
we measured the volume of hippocampus in animals belonging to
both VEH and RESV groups. This analysis revealed that both VEH-
and RESV-treated animals exhibited comparable hippocampal
volumes (VEH group, Mean 6 SEM 5 27.57 6 1.01 mm3, RESV
group, 27.79 6 1.63 mm3, p . 0.05). Thus, the beneficial effects
mediated by RESV did not change the overall volume of
hippocampus.
Discussion
The results of this study in a rat model of aging provide new evidence
that RESV treatment in late middle age can positively modulate the
structure and function of the aged hippocampus. The structural
changes that occurred with RESV treatment comprised increased
neurogenesis and microvasculature, and reduced astrocyte hyper-
trophy and activation of microglia. The beneficial functional effects
included improved ability for spatial learning, preserved proficiency
for making new spatial memory, and alleviation of depressive-like
behavior associated with aging. Because decreases in neurogenesis
and microvasculature, and increases in astrocyte hypertrophy and
activation of microglia during aging can adversely affect cognitive
andmood function, the structural plasticitymediated by RESV in the
aged hippocampus have likely contributed greatly towards beneficial
functional effects.
Rationale for using RESV for mitigating age-related cognitive,
memory and mood dysfunction. Decline in cognitive capacity
after middle age is seen in most humans as well as in animal
models. In humans, this may manifest in the form of occasional
forgetfulness, decreased processing speed and mental flexibility,
and reduced ability for solving problems or maintaining
attentiveness41. Although these problems in milder forms are
typical for the elderly population, progression of these snags into a
measurable decline in cognition and memory would result in a
Figure 6 | Newly born neurons expressing doublecortin (DCX) in the subgranular zone-granule cell layer (SGZ–GCL) of rats treated with vehicle (VEH;
A1) or resveratrol (RESV; B1, C1). (A2, B2 and C2) are magnified views of regions from (A1, B1 and C1). Comparison of numbers of DCX1 newly
born neurons betweenVEH andRESV treated groups (bar chart inD, n5 6/group) revealed greatly enhanced production of newly born neurons in RESV
treated aged animals (p, 0.001, two-tailed, unpaired Student’s t-test). DH, dentate hilus; ML, molecular layer. Scale bar, (A1, B1 and C1), 100 mm; (A2,
B2 and C2), 50 mm. ***, p , 0.001.
www.nature.com/scientificreports
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Figure 7 | Distribution of rat endothelial cell antigen-1 (RECA-1)-positivemicrovessels and glial fibrillary acidic protein (GFAP)-positive astrocytes in
vehicle (VEH) and resveratrol (RESV) treated groups. (A1–C2) compare the distribution of RECA-11 microvessels in the dentate gyrus (DG, A1, A2),
the CA1 subfield (B1, B2) and the CA3 subfield (C1, C2) of the hippocampus between VEH treated (A1, B1, C1) and RESV treated (A2, B2, C2) animals.
Bar charts in D1–D4 compare area fraction of RECA-11 structures in different regions of the hippocampus between the two groups (n5 6/group). Note
that, RESV treatment increased the area fraction of RECA-11 structures in the CA1 subfield and the entire hippocampus (D2, D4; p, 0.05–0.01, two-
tailed, unpaired Student’s t-test). (E1–G2) compare the distribution andmorphology of GFAP1 astroctyes in the DG (E1, E2), the CA1 subfield (F1, F2)
and the CA3 subfield (G1, G2) of the hippocampus between VEH treated (E1, F1, G1) and RESV treated (E2, F2, G2) animals. Bar charts (H1–H4)
compare area fraction of GFAP1 structures in different regions of the hippocampus between the two groups (n 5 6/group). Note that, RESV treatment
considerably decreased the area fraction of GFAP1 structures in all subfields of the hippocampus as well as for the entire hippocampus (H1–H4, p ,
0.001). Scale bar, (A1–C2 and E1–G2), 25 mm. *, p , 0.05, **; p , 0.01; ***; p , 0.001.
www.nature.com/scientificreports
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Figure 8 | Distribution of OX-42 (CD11b)-positive microglia in the hippocampus of vehicle (VEH) and resveratrol (RESV) treated groups. (A1–C2)
compare the distribution and morphology of OX-421 microglia in the dentate gyrus (DG, A1, A2), the CA1 subfield (B1, B2) and the CA3 subfield (C1,
C2) of the hippocampus between VEH treated (A1, B1, C1) and RESV treated (A2, B2, C2) animals. E1 and E2 show representative examples ofmicroglial
morphology traced with Neurolucida from VEH treated (E1) and RESV treated (E2) rats. Most microglia in VEH-treated aged rats exhibited enlarged
soma, shorter processess and reduced ramification of processes (arrows in A1, B1, C1, and the cartoon in E1), implying a tendency towards conversion
into amoeboid or activated microglia. In contrast, most microglia in RESV treated rats maintained longer processes with extensive ramifications
(arrowheads in A2, B2, C2, and the cartoon in E2) suggestive of resting microglia. Bar charts in (D1–D4) compare area fraction of OX-421 structural
elements in different regions of the hippocampus between the two groups (n 5 7/group). RESV treatment increased the area fraction of OX-421
structures in the CA1 subfield and the entire hippocampus (D2, D4; p, 0.05, two-tailed, unpaired Student’s t-test). Bar charts in (F1–F4) compare the
number of segments (F1), the total process length (F2), the number of intersections (F3) and the number of process endings (F4) inmicroglia traced from
VEH and RESV treated aged animals (n 5 42 microglia/group). Note that RESV treated animals displayed greater numbers of segments (F1, p, 0.01),
increased process length (F2, p, 0.05), increased numbers of intersections at 0–10 mmand 20–30 mmdistances from the soma (F3, p, 0.05), and greater
numbers of process endings (F4, p , 0.05). Scale bar, (A1–C2 and E1–G2), 25 mm; (E1–E2), 10 mm. *, p , 0.05, **; p , 0.01.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8075 | DOI: 10.1038/srep08075 10
clinical condition called MCI. Because people with MCI have an
increased risk for developing AD or other type of dementia2,
interventions that can improve cognitive and memory function in
old age or prevent MCI in old age have immense importance. A
multitude of factors including myelin loss, thinning of the cerebral
cortex, decreased hippocampus volume, reduced neurotransmitter
concentrations, altered neuronal networks associated with decreases
in neuron size and synaptic density can contribute to cognitive
decline with aging41,42. On the other hand, memory and mood
dysfunction in old age has been linked strongly to decreased
function of DG in the hippocampus3,4. There are several structural
changes in the aged DG that parallel its diminished function. Greatly
reduced neurogenesis is one of the conspicuous alterations attracting
the most attention because of its purported role in learning, memory
and mood function6,14,13,20. Additional structural changes in the DG
include diminished ability of interneurons to synthesize the
inhibitory neurotransmitter gamma-amino butyric acid (GABA)
resulting in compromised inhibitory synaptic transmission43,44, and
loss of synapses between DG granule cells and perforant path
afferents from the entorhinal cortex42. However, these changes are
likely secondary to multiple primary age-related alterations in the
DG. These include decreased blood flow due to loss of
microvasculature, endothelial cell dysfunction or plaques in
cerebral blood vessels29, increased oxidative stress45, chronic low-
level inflammation in the form of hypertrophy of astrocytes and
activation of microglia26,27, and reduced concentration of astrocyte-
derived pro-neurogenic and pro-angiogenic factors and signaling
molecules22–25,28. If the above proposition is true, then, therapeutic
interventions that reverse one or more of the primary age-related
changes in the brain should improve cognitive andmood function in
the aged population. Indeed, several earlier studies have shown that
administration of nutraceuticals having ability to suppress oxidative
stress and/or inflammation or low-doses of antiepileptic drugs
capable of increasing GABA-ergic neurotransmission can improve
memory function in aging rodents44,46–48.
We chose RESV in this study because of its ability to readily cross
the blood-brain barrier following peripheral administration, pro-
mote angiogenesis, suppress oxidative stress, inflammation and
mitochondrial dysfunction, activate longevity genes and extend life
span without adverse side effects31–35,37. Moreover, RESV treatment
can mimic caloric restriction, a strategy that has been found to exert
several beneficial effects on the aging brain49,50. Furthermore, pre-
vious studies have shown that RESV treatment can provide protec-
tion against neurodegeneration inmodels of AD51, improve cognitive
function in adult primates52 and enhance hippocampal microvascu-
lature in aging mice53. In addition, recent studies report that RESV
treatment can improve memory performance in healthy older per-
sons38 and promote antidepressant effects in an animal model of
depression39. Our goal was to determine whether short-term RESV
treatment in late middle age can improve cognitive and mood func-
tion in old age and whether any improvements in cognitive and
mood function seen with RESV treatment will be associated with
improved neurogenesis and microvasculature and/or suppression
of chronic low-level inflammation typically seen in the aged
hippocampus.
Mechanisms underlying RESV-mediated improvements in learning,
memory andmood function in aged rats. To understand mechanisms
underlying RESV-mediated beneficial effects on learning, memory and
mood, we quantified the extent of neurogenesis, microvasculature,
astrocyte hypertrophy and activation of microglia in the
hippocampus. These are measures that are known to undergo
alterations in old age and substantial changes in them can adversely
influence memory and mood. First, it is clear that aging is associated
with greatly waned hippocampal neurogenesis, and memory and mood
dysfunction in aging can be attributed at least partially to greatly
decreased neurogenesis. This is because: (i) increased hippocampal
neurogenesis in middle-aged and aged animals exposed to enriched
environment is allied with increased ability for making new spatial
memories17,18; (ii) aged rats having ability for forming new spatial
memories display higher levels of hippocampal neurogenesis than
impaired aged rats54,55; (iii) middle-aged mice exercising on running
wheels or having lowered stress hormone levels demonstrate both
enhanced hippocampal neurogenesis and better memory ability15,16;
Figure 9 | Distribution of ED-1 (CD68)-positive activated microglia in the dentate hilus (DH) and granule cell layer (GCL) of vehicle (VEH, A1) and
resveratrol (RESV, A2) treated groups. (B1 and B2) are magnified views of dentate hilar regions from A1 and B2. The bar chart in C compares
numbers of ED-11 activated microglia between VEH and RESV treated rats (n 5 6/group). Values represent means and standard errors. Note that, the
RESV treated group exhibited decreased numbers of ED-11 activated microglia than the VEH treated group (p, 0.05, two-tailed, unpaired Student’s t-
test). Scale bar, (A1–A2), 100 mm; (E1–E2), 50 mm. *, p , 0.05.
www.nature.com/scientificreports
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(iv) aged rats displaying ability for making new spatial memories exhibit
enhanced survival of new cells generated just prior to the onset of
learning56; and (v) progenitor cells in the hippocampus of depressed
patients exhibit decreased proliferation than age-matched controls19.
Second, it has been demonstrated in earlier studies that aging is
associated with degenerative changes in cerebral capillaries causing
decreased microvasculature, reduced blood flow, disruption of the
blood-brain barrier and increased infiltration of CD451 macrophages
in the hippocampus29,57. It is believed that these changes in
microvasculature contribute to memory dysfunction in aging29,57.
Third, chronic low-level inflammation is one of the conspicuous
features of the aged rodent and human hippocampus58, which can be
gauged through changes in the morphology of astrocytes andmicroglia.
Astrocytes in the aged hippocampus display reactive phenotype and a
significant fraction of microglial cells in the aged hippocampus
undergoes activation. This kind of chronic low-level inflammation in
the aged hippocampus can adversely affect memory and mood
function. For example, systemic inflammation induced pro-
inflammatory changes in the hippocampus causes deficits in the
hippocampal long-term potentiation (LTP, a basis of learning and
memory) in middle-aged rats and antiinflammatory therapy restores
LTP in these rats59.
Interestingly, RESV treatment enhanced net neurogenesis in the
last week of RESV treatment, and maintained increased neurogenesis
and microvasculature when examined at,25 months of age (i.e.,6
weeks after the termination of RESV treatment). Furthermore, RESV
treatment had antiinflammatory effects in the form of reduced hyper-
trophy of astrocytes and diminished activation of microglia. The
microvasculature enhancing effects of RESV noted here is consistent
with earlier findings that RESV treatment improves endothelial func-
tion and cerebral blood flow60,61, whereas its antiinflammatory effects
are in line with a previous study showing that RESV can reduce
plasma levels of pro-inflammatory cytokines62. On the other hand,
neurogenesis-enhancing effects of RESV in the aged hippocampus are
likely mediated through increased microvasculature and suppression
of inflammation in the neurogenic niche (i.e. SGZ of the DG), as both
decreased vasculature/blood flow and inflammation can adversely
affect the proliferation of NSCs and neurogenesis63.
Thus, the precise reasons underlying a diminished spatial learning
ability and an impaired memory function in VEH-treated aged ani-
mals and improved spatial learning and memory ability in RESV-
treated aged rats are unknown. However, as age-related memory
dysfunction typically occurs between 18 and 24 months of age in
male F344 rats64, it is plausible that impaired spatial learning and
memory function in VEH-treated animals is linked to multiple
adverse changes in the aged hippocampus that are detailed above.
Additional age-related changes observed in earlier studies such as
alterations in dendritic morphology, cellular connectivity, gene
expression and other factors affecting plasticity and network
dynamics of neural ensembles supporting cognition and memory
may also be involved65. On the other hand, improved memory
retrieval function in RESV-treated animals is likely owed to multiple
RESV-mediated beneficial changes, which may include increased
neurogenesis and microvasculature and dampened inflammation
described above. Several molecular mechanisms are expected to be
involved in mediating these beneficial changes. These could com-
prise increased expression of SIRT1 (nicotinamide adenine dinucleo-
tide-dependent histone deacetylase), a longevity factor that
undergoes upregulation with RESV treatment and is believed to play
a role in the maintenance of normal cognitive and mood function
and neurogenesis66,67. Indeed, a parallel study in our laboratory has
shown that four weeks of oral RESV treatment to aged rats increased
the expression of SIRT1 gene as well as its down-stream target
FOXO368, a transcription factor that regulates the capacity of cells
to cope with endoplasmic reticulum and oxidative stress69.
Furthermore, alteration in the expression of nuclear factor kappa B
(NF-kB), a transcription factor responsible for the regulation of mul-
tiple target genes related to inflammation, could be involved in the
suppression of inflammation, as RESV treatment has been shown to
modulate NF-kB pathways in several models70,71. In addition, activa-
tion of adenosine monophosphate (AMP) activated protein kinase
(AMPK), a protein kinase having a major role in neuronal differenti-
ation andmitochondrial biogenesis in neurons, may also be involved,
as RESV is known to up-regulate AMPK in a SIRT1-dependent
manner66. Furthermore, mechanisms such as an improved glucose
metabolism and enhanced functional connectivity between the pos-
terior hippocampus and the medial prefrontal cortex observed in a
recent human study38, reduction in serum corticosterone and regu-
lation of the hypothalamus-pituitary-adrenal (HPA) axis72 and
enhanced brain-derived neurotrophic factor (BDNF) signaling
pathway39,73 may also be contributing to RESV-mediated improved
cognitive and mood function. Studies on these aspects at different
time-points after RESV treatment in aging models will be needed in
the future to understand their role.
Another remarkable attribute of this study is that improved cog-
nitive function in aged rats following RESV treatment differed from
an earlier study on the effects of RESV treatment in juvenile (4-weeks
old)mice74. This study showed that administration of RESV to juven-
ile mice reduced hippocampal neurogenesis as well as cognitive func-
tion, in association with activation of AMPK and down-regulation of
the phosphorylated form of cyclic AMP response element-binding
protein (pCREB) and BDNF in the hippocampus. The discrepancy
reflects divergent effects of RESV on the juvenile vis-a`-vis the aged
brain. Administration of RESV in the juvenile age corresponds to a
time when the hippocampus was still maturing with very high levels
of neurogenesis. This is in sharp contrast to the current study where
RESV was administered at a time when the aged hippocampus was
exhibiting a greatly declined neurogenesis, reduced cerebral blood
flow, chronic low level inflammation and increased oxidative stress.
It is likely that inflammation, oxidative stress and reduced cerebral
blood flow in the aged brain contributed to the reduced neurogenesis
and impaired cognitive function and RESV treatment enhanced neu-
rogenesis and microvasculature through antiinflammatory, antiox-
idant and pro-angiogenic effects, which in turn improved cognitive
function in aged rats. On the other hand, since the juvenile brain does
not normally display inflammation, increased oxidative stress or
decreased cerebral blood flow, RESV-mediated suppression of nor-
mal levels of oxidative stress that are believed to be required for
neural stem cell (NSC) proliferation and differentiation75 may have
impaired neurogenesis and interfered with the cognitive function in
juvenile mice. The observed opposing effects of RESV on the juvenile
vis-a`-vis the aged brain also imply that RESV treatment can have
beneficial effects in a background of a disease state or in conditions
such as aging, but may adversely affect function of the developing or
the young brain74. Additional longitudinal studies over the lifespan of
animals will be useful to comprehend the mechanisms underlying
these differences. Nonetheless, the beneficial effects of RESV treat-
ment for the aged brain is also apparent from a recent human study,
which demonstrated that lower dose of RESV intake for 26 weeks can
improve memory performance as well as hippocampus functional
connectivity in healthy but overweight older individuals38.
Additionally, our study on the effects of oral administration of a
higher dose of RESV (90 mg/Kg) is supportive, which showed that
preserved memory function in aged rats receiving RESV was assoc-
iated with increased expression of multiple genes encoding cognitive
function and neurotrophic factors68.
Conclusions
Our results in a rat model of aging provide novel evidence that four
weeks of daily RESV treatment in late middle age is efficacious for
improving cognitive, memory and mood function in old age.
Additional analyses demonstrated that improved cognitive and
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mood function following RESV treatment is linked with ameliora-
tion of several age-related changes such as decreased neurogenesis
and microvasculature and low-level chronic inflammation in the
hippocampus. These results suggest that RESV therapy in middle
age is beneficial for maintaining normal memory andmood function
in old age.
Methods
Animals and research design.Twenty-onemonth oldmale Fischer 344 rats acquired
from Harlan Sprague-Dawley (Indianapolis, IN, USA) were used in this study. All
experiments were performed as per the animal protocol approved by the animal
studies subcommittee of the Durham Veterans Affairs Medical Center. Following
arrival, animals were allowed to have 7–10 days acclimatization in the vivarium.
Animals for this study were chosen from a larger cohort of aged rats (n 5 80) that
were screened for hippocampus-dependent spatial learning andmemory ability using
Morris WMT76 for several different studies in the laboratory. Figure 1 illustrates the
time-line of various treatments and analyses. Animals with normal spatial learning
and memory function were chosen and divided into two groups. One of the groups
then received daily intraperitoneal injections of RESV (n 5 8, 40 mg/Kg dissolved in
0.5 ml of 2% ethyl alcohol, Sigma-Aldrich, St. Louis, MO, USA) while the other group
received daily intraperitoneal injections of VEH solution (n 5 7) for four weeks. The
dose of RESV was based on findings in our preliminary studies using middle-aged
rats, where this dose increased hippocampal neurogenesis. We chose intraperitoneal
injections in this study because we wanted to examine the effects of a relatively lower
dose of RESV for a shorter duration (4 weeks). The drug was injected into areas in the
left or right halves of the peritoneal cavity alternatively to minimize repeated
injections at one site and peritoneal irritation. Following injections, animals were
closely monitored and no writhing behavior was observed. Thus, animals did not
show signs of dermal or peritoneal irritation because of very lower concentration of
alcohol used as vehicle in this study.
In order to label newly born cells and neurons in the hippocampus animals in both
groups also received BrdU (100 mg/kg) injections during the last 7 days of RESV
treatment. A month after RESV treatment, a fresh round of WMT was conducted.
Following this, the extent of depressive-like behavior was quantified using an FST. In
order to determine the production of new cells and the status of hippocampus neu-
rogenesis, stereological quantifications of cells positive for BrdU and DCX were
performed for the SGZ-GCL of the DG using serial sections (every 10th) immunos-
tained for BrdU orDCX and StereoInvestigator (Microbrightfield Inc.,Williston, VT,
USA). Furthermore, to ascertain net hippocampus neurogenesis, analyses of BrdU1
cells expressing NeuN were carried out for the SGZ-GCL using confocal microscopy
and Z-section analyses. To determine the effects of RESV on other structural changes
in different subfields (DG, CA1 and CA3) of the hippocampus, we also quantified
areas occupied by the microvasculature, astrocytes and microglia through
immunohistochemical staining of serial sections (every 15th through the hip-
pocampus) for RECA-1 (a marker of cerebral blood vessels), GFAP (a marker
astrocytes), OX-42 (a marker of microglia) and area fraction analyses using J Image.
Moreover, to distinguish any changes in the morphology, we quantified processes of
microglia using Neurolucida (Microbrightfield). Additionally, to quantify the frac-
tion of microglia that was activated in the vicinity of the neurogenic region, we
performed ED-1 immunohistochemistry using serial sections (every 15th) and
quantified the numbers of activated microglia in the DG using StereoInvestigator.
Analyses of hippocampus-dependent spatial learning and memory function.
Hippocampus-dependent spatial learning and memory function in aged rats was
analyzed using a WMT, as described in our recent studies77,78. A circular water maze
tank (measuring 170 cm in diameter and 75 cm in height) was filled with water at
room temperature to 35 cmheight. Thewater was rendered opaque by the addition of
a white, non-toxic paint, and extra-maze cues were positioned on the walls of the
room around the tank. The pool was arbitrarily divided into four equal quadrants and
a circular platform (15 cm diameter) was submerged 1 cm below the water surface in
the middle of one quadrant. A quartz halogen lamp was positioned aiming at the
ceiling to indirectly illuminate the water surface. A video camera was mounted on the
ceiling directly above the center of the pool and themovement of rat in thewatermaze
tank was continuously video-tracked and recorded using a computerized ANY-Maze
video tracking system (Stoelting ANY-maze, Wood Dale, IL, USA). The rat was
trained to find the platform using spatial cues for 7 sessions over 7 days with 4
acquisition trials per session. Each rat was placed in the water, immediately facing the
wall of the tank in one of the quadrants in pseudo-randommanner, and then allowed
a maximal time of 90 seconds to locate the platform with an inter-trial interval of 120
seconds. Each trial commenced from a different start location. When the subject
reached the platform it was allowed to stay there for 30 seconds. When the subject
failed to find the platformwithin the ceiling time of 90 seconds, it was guided onto the
platform and allowed to stay there for 30 seconds. The platform was positioned in the
same place across all sessions. Data such as the latency and swim path lengths to reach
the platform, swim path efficiency (the ratio of the shortest possible swim path length
to actual swim path length), and swim speed were collected using Anymaze software.
Mean latencies to reach the platform were used for assessment of learning curves, as
swim speeds did not differ between groups in this study. A day after the 7-day learning
protocol described above, each rat was subjected to a single 45-second probe or
memory retrieval test. This involved removal of the platform from the pool and
release of rats from the quadrant that is diametrically opposite to the quadrant where
the platform was positioned during learning sessions. Retrieval of learned memory
was assessed by comparing dwell time in the PQwith the other three quadrants within
the group and also by comparing dwell time in platform quadrant, latency to reach the
platform area, dwell time in platform area and platform area crossings across groups.
Characterization of depressive-like behavior. An FST was employed for assessing
depressive-like behavior in aged rats (n 5 7–8/group), as the validity of FST as a
measure of depressive-like behavior has been suggested in many previous studies79,80.
This test was done as detailed in our recent studies78,81. In brief, 24 hours after the
completion of WMT, each rat was placed in an acrylic glass cylinder having a
diameter of 18.7 cm and depth of 42 cm and containing room temperature (25uC)
water to a depth of 30 cm. This ensured that the rat could not touch the bottom of the
cylinder with its tail or hind paws or escape from the top. The rat was subjected to a
single session of forced swimming lasting ten minutes. We directly performed the
forced swimming trial, as this test was conducted two days after the completion of
WMT. Since animals have experienced swimming during learning sessions in the
WMT, a separate swimming trial was not given prior to testing in an FST. Animal
behavior during the test wasmonitored and recorded by a video camera. Investigators
scored immobility time for each animal using the recorded videos. Animals that
exhibited signs of drowning behavior were quickly removed from the cylinder and
excluded for FST analyses. The amount of time spent in immobility (also referred to
as floating) was calculated later. Immobility is defined as the minimal movement
necessary to keep the head above the water level. The amount of time spent in floating
was used as ameasure of depressive-like behavior and compared between groups (n5
5–6/group). Furthermore, we compared FST data in two separate segments (5
minutes each). This is because typically in the first 5 minutes of the test, normal
animals (i.e. animals having no depression) tend to swim continuously with minimal
time spent in immobility in contrast to depressed animals spending greater amount of
time in immobility. In the last 5 minutes of the test, even a normal rat may display
increased immobility due to swimming related fatigue. Therefore, analysis of two
segments of FST time helps to dissociate depression-related immobility from fatigue-
related immobility.
Tissue processing and immunohistochemistry. Animals underwent intracardiac
perfusions with 4% paraformaldehyde solution prepared in phosphate buffer (PB).
Each animal was first deeply anesthetized with isoflurane in a Plexiglas chamber until
it ceased respiration. Following this, the chest was surgically opened, the heart was
exposed, a nick was made in the right atrium, and sequentially infused with normal
saline and 4% paraformaldehyde through the left ventricle. The brains were dissected,
post-fixed overnight in 4% paraformaldehyde solution, washed in PB, and treated
with different concentrations (10–30%) of sucrose until they sank to the bottom of the
container. Each brain was then mounted on a cryostat chuck and 30-micrometer
thick coronal sections through the hippocampus were cut and collected serially in 24-
well plates. Two sets of serial sections (every 10th) through the entire hippocampus
were picked from each animal belonging to RESV and VEH control groups and
processed for BrdU and DCX immunostaining, as described in our previous
studies12,13,82,83. In order to measure the fraction of BrdU1 cells that express the
mature neuronal marker neuron-specific nuclear antigen (NeuN) in the SGZ-GCL,
another set of serial sections (every 15th) through the hippocampus was processed for
BrdU and NeuN dual immunofluorescence staining, as described in our earlier
reports84. Furthermore, additional sets of serial sections (every 20th) through the
hippocampus were processed for immunohistochemical characterization of cells
positive for RECA-120, GFAP23, OX-4222 and ED-177. The primary antibodies
comprised monoclonal antibodies against BrdU (15500, BD Biosciences, San Jose,
CA, USA or 15200, Serotech, Raleigh, NC, USA), NeuN (151000, EMD Millipore,
Darmstadt, Germany), OX-42 (15500, AbD Serotech), RECA-1 and ED-1 (151000,
AbD Serotech), and polyclonal antibodies against DCX (15250; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and GFAP (152000, Dako, Carpinteria, CA,
USA).
Stereological quantification of BrdU1 cells, DCX1neurons andED-11 activated
microglia. Numbers of BrdU1 newly born cells and DCX1 newly born neurons in
the SGZ-GCL, and ED-11 activated microglia in the entire DG, were stereologically
measured using the optical fractionator method (n 5 6 animals/group). For this, we
used 30-micrometer thick serial sections (every 10th for BrdU andDCX and every 20th
for ED-1 analyses) through the entire hippocampus and the StereoInvestigator
system (Microbrightfield) comprising a color digital video camera (Optronics Inc.,
Muskogee, OK, USA) interfaced with a Nikon E600 microscope, as detailed in our
earlier publications40. In brief, the contour of the chosen counting region (SGZ-GCL
or the entire DG) was marked in every section, the optical fractionator component
was activated, and the density and location of counting frames (each measuring 40 3
40 mm) and the counting depth were determined by entering parameters such as the
grid size (75 mm), the thickness of top guard zone (4 mm) and the optical dissector
height (i.e. 8 mm). A computer driven motorized stage then allowed the cells to be
measured at each of the counting frame locations. In every location, the top of the
section was set, and the plane of the focus was moved 4 mm deeper through the
section (guard zone). This plane served as the first point of the counting process. All
cells that came into focus in the next 8 mmsection thickness were counted if they were
entirely within the counting frame or touching the upper or right side of the counting
frame. This procedure was repeated for all serial sections. By utilizing parameters
such as the initial section thickness (i.e. at the time of sectioning), the section
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thickness at the time of cell counting (i.e. after immunostaining), and cell counts from
the counting frame locations, the StereoInvestigator program calculated the total
number of BrdU1/DCX1/ED-11 cells per SGZ-GCL or the entire DG, as described
in our earlier studies12,13. The Gundersen coefficient error (CE) was in the range of
0.05–0.15 for all counts in this study.
Measurement of BrdU1 cells expressing the mature neuronal marker NeuN. The
sections processed for BrdU and NeuN dual immunofluorescence were analyzed
using a laser scanning confocal microscope (FV-10i, Olympus), as described in our
earlier reports84. The Z-stacks taken at 1-mm intervals were analyzed for identification
of cells dual labeled for BrdU and NeuN and the percentages of BrdU1 cells
expressing NeuN were computed.
Quantitative analyses of RECA-11, GFAP1 and OX-421 structures in the
hippocampus. The areas occupied by RECA-11 vascular, GFAP1 astrocyte, and
OX-421 microglial elements (area fractions) were measured per unit area of the
tissue in the DG, and CA1 and CA3 subfields of the hippocampus, as described in our
recent study81. This quantification was accomplished through Image J for Windows
(n 5 6–7 animals/group). In brief, microscopic images from different regions of the
hippocampus were digitized using 203 objective lens in a Nikon E600 microscope
equipped with a digital video camera connected to a computer. Each image saved in
gray scale as a bitmap file was opened in Image J, and a binary image was created
through selecting a threshold value that kept all RECA-11/GFAP1/OX-421
immunostained elements but no background. The area occupied by the RECA-11/
GFAP1/OX-421 structures (area fraction) in the binary image was then measured
by selecting the Analyze command in the program. Area fraction of RECA-11/
GFAP1/OX-421 structures was calculated separately for every hippocampal region
in each animal by using data from all chosen serial sections before the means and SEs
were determined for the total number of animals included per group (n 5 6–7).
Morphometry ofmicroglia expressingOX-42.The overall morphology of microglia
were compared between RESV and VEH treated groups by measuring processes of
randomly selected but well stained OX-42 microglial cells from both groups. These
measurements were made using a semiautomatic neuron tracing system
(Neurolucida; Microbrightfield) linked to a Nikon microscope. In each group, forty-
two OX-421 microglial cells (from 7 animals) were individually traced in their
entirety using oil immersion 1003 lens, and data for the number of processes and
total process length were computed. To measure the extent of process growth away
from the soma and the branching of processes at different distances from the soma,
the concentric circle analysis of Sholl was performed using NeuroExplorer
component of the Neurolucida program.
Measurement of the volume of hippocampus. The volume of hippocampus was
measured through tracing of the outer margin of the hippocampus (including
fimbria, n 5 6 animals/group), using serial coronal brain sections (every 15th)
through the entire hippocampus immunostained for DCX. A semiautomatic tracing
system (Neurolucida, Microbrightfield) linked to a Nikon microscope was employed
for these measurements.
Statistical analyses. All statistical analyses were done using Prism software. Data
pertaining to spatial learning (latencies to reach the platform in successive learning
sessions and swim path efficiency) were compared between groups using two-way
RM-ANOVA followed by Bonferroni’s multiple comparisons test. The major results
of probe tests (e.g. dwell time in platform quadrant versus all other quadrants) were
compared using one-way ANOVA followed by Newman-Keuls multiple
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